{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030719","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.673922+00:00","generated_at":"2026-05-17T04:17:44.955215+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker","bullets":["In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.","Neflamapimod reduced the risk of clinically meaningful progression by 75% vs placebo over 16 weeks (p<0.001).","Plasma GFAP levels decreased by median -23.1 pg/mL on neflamapimod vs +5.8 on placebo (p=0.016); GFAP change correlated with CDR-SB.","FDA feedback on Phase 3 trial design expected in Q4 2025.","Two drug capsule batches were used; only the newer batch (NFMD/B) achieved target plasma concentrations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030719","json":"https://secwatch.observer/filing/0001437749-25-030719.json","markdown":"https://secwatch.observer/filing/0001437749-25-030719.md","text":"https://secwatch.observer/filing/0001437749-25-030719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/0001437749-25-030719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/crvo20251008_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:17:44.955215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}